At AI Summit Budapest, the Digi4Care case study pulled the conversation out of the lab and into clinics. Partners running AI‑supported diabetic retinopathy screening across four countries in the Danube Region described a simple truth: the same model behaves very differently once it meets real people, real networks, and real payment rules. According to the project’s own summary, the work brought together leaders from Bulgaria, the Czech Republic, Austria, and Hungary to compare what worked and what stalled in day‑to‑day care (Interreg Danube DIGI4Care).
What the Digi4Care case study revealed on the ground
The pilot focused on AI‑supported screening for diabetic retinopathy, a leading cause of preventable vision loss. The technology layer was constant; the pathway around it was not. As the session reported, who conducts the scan, who follows up, who owns clinical responsibility, and who pays for the visit varied widely across the four systems (Interreg Danube DIGI4Care). Peter Pažitný, a health economist on the panel, summed up the lesson: “the success of the technology is not the technology itself” — it’s whether the tool fits a living workflow people accept and can run.
That observation cuts against much of the hype. In eye‑screening, sensitivity and specificity dominate headlines. In deployment, appointment flows, referral loops, and billing codes decide scale. The Digi4Care case study made that gap visible.
Same AI, different systems: who screens, who follows up, and who pays
Screening can sit in primary care, pharmacy, or ophthalmology. Follow‑up might be a rapid‑access clinic in one system and an external referral in another. Accountability can rest with the image taker, the interpreting clinician, or a supervising service. Payment may come from a bundled chronic‑care program, a specialist tariff, or no code at all. The panel described each of these choices as structural forks that shape adoption, not side notes (Interreg Danube DIGI4Care).
Those variations are not unique to the Danube Region. Global guidance frames regular retinopathy screening as essential for people with diabetes, but it leaves room for countries to organize care in different ways. That flexibility is a feature for policy, and a constraint for product rollout. It means procurement teams must tailor deployment plans country by country, sometimes facility by facility — including how results return to electronic records and how patients move to treatment. For wider clinical context, the World Health Organization describes diabetic retinopathy as a major cause of vision impairment and emphasizes organized screening and timely treatment as core strategies (WHO: Diabetic retinopathy).
From Wi‑Fi to training: the unglamorous blockers the Digi4Care study surfaced
The panel’s most practical warning was about infrastructure humility. A hospital’s assurance that “we have Wi‑Fi” did not always translate into stable coverage where a connected fundus camera sat. Dead zones and flaky uplinks slowed exams and broke uploads. Digital literacy varied among clinicians and patients. Readiness differed across devices. And without fast technical support, small glitches piled up into missed screenings. The project cited regulation and reimbursement as the final gate — if the service lacked a clear code, the pilot risked becoming an unfunded extra shift (Interreg Danube DIGI4Care).
These are solvable problems, but they need to be named and budgeted. Even mature AI tools can fail if the last 50 meters of connectivity, workflow, and payment are unplanned. Health systems that treat those layers as afterthoughts tend to strand good pilots in “demo” status.
Why these lessons matter beyond eye screening
Diabetic retinopathy is a revealing testbed because the clinical need is large and the pathway is well understood. Models that flag referable disease can widen access in primary care and point more patients to timely treatment. That promise is real; autonomous and assistive systems for retinopathy screening have already cleared regulators in several markets, including the United States (FDA announcement on autonomous DR screening).
Yet the Digi4Care case study shows how scale depends on the care pathway and the payer, not just the model. That lesson travels to other specialties: chest X‑ray triage, dermatology, cardiovascular risk scoring, and readmission prediction share the same failure modes. If you cannot say who acts on the alert, where the result lives, and how the session is reimbursed, you are not ready to deploy.
Policy groups tracking AI in health reach similar conclusions. Comparative analyses stress that adoption hinges on governance, workforce skills, and financing design as much as on accuracy claims. For a broader view, the OECD’s work on AI in healthcare points to the need for clear accountability and sustainable payment to move from pilots to services (OECD: AI in healthcare).
A one‑page playbook for hospital leaders
The panel’s insights can be turned into a practical starter plan. Before buying devices or booking a launch date, lock down the following:
- Map the pathway end to end: who performs the screen, who validates results, who informs the patient, who books treatment, and how data reach the EHR.
- Verify connectivity at the point of care: run speed and stability checks where the device sits, and plan for offline mode or buffered uploads if needed.
- Define accountability on paper: name the clinician or service that owns the decision to refer, and how oversight works for AI‑assisted or autonomous outputs.
- Secure reimbursement: identify billing codes or payment programs, run test claims, and agree on who bears costs during ramp‑up.
- Train two audiences: clinical users on workflow and limits; operational staff on device upkeep, user management, and support routing.
- Stand up support: a response path for day‑one glitches, remote monitoring for device health, and a clear contact tree.
- Measure what matters: screening throughput, image reject rates, referral volumes, time‑to‑treatment, and patient experience — reviewed weekly at first.
- Cover safety and ethics: document consent, escalation for uncertain cases, and a process to audit model output for bias or drift over time.
None of these steps require new science. They require ownership and time on the calendar. They also give boards and payers a way to ask better questions before approving money or headcount.
What the Digi4Care case study means for the next wave
The Digi4Care partners did the hard thing: they moved beyond proof‑of‑concept and compared real deployments across borders. Their message is plain. Accuracy matters, but adoption is built on workflows, training, connectivity, and payment. Teams that design for those layers will see AI become ordinary care faster. Those that skip them will keep staging the same flashy demo, then shelving it.
As systems plan the next tranche of AI‑supported services, they would do well to borrow the frame from AI Summit Budapest. Treat the model as one component. Engineer the pathway around it with the same care. The Digi4Care case study shows that is the difference between a pilot and a program. For more on this, see nytimes.com.